Alti-Salbutamol Inhalation Aerosol and Imodium Multi-Symptom Relief
Determining the interaction of Alti-Salbutamol Inhalation Aerosol and Imodium Multi-Symptom Relief and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using excessive doses of loperamide can cause serious and potentially fatal complications such as irregular heart rhythm and cardiac arrest, and the risk may be increased when combined with other medications that can also cause cardiac problems such as albuterol. You may also be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Do not exceed the dose and frequency or duration of use of loperamide recommended on the product label or prescribed by your doctor. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval. Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. According to the FDA, the agency received reports of 48 cases of serious heart problems associated with use of loperamide from when it was first approved in 1976 through 2015. Thirty-one of these cases resulted in hospitalizations, and 10 patients died. The serious heart problems occurred mostly in patients who were using loperamide dosages that were much higher than recommended in an attempt to achieve euphoria, prevent opioid withdrawal, or treat diarrhea. In the most severe cases, individuals self-treated with dosages ranging from 70 to 1600 mg/day, or 4 to 100 times the recommended dosage. In other cases, patients were taking the recommended dosage, but with concomitant interacting drugs that caused an increase in loperamide levels. There have been additional cases of serious heart problems associated with loperamide use reported in the medical literature. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy. In many of the reported cases of loperamide-induced cardiotoxicity, standard antiarrhythmic drugs were ineffective, and electrical pacing or cardioversion was necessary.
- Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6
- US Food and Drug Administration "FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM505108.pdf." ([2016, Jun 7]):
Generic Name: albuterol
Brand name: ProAir HFA, ProAir RespiClick, Proventil HFA, Ventolin HFA, Accuneb, ProAir Digihaler, Proventil, VoSpire ER
Synonyms: Albuterol Inhalation, Albuterol
Generic Name: loperamide / simethicone
Brand name: Imodium Multi-Symptom Relief
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Alti-Salbutamol Inhalation Aerosol-Imogam Rabies-HT
- Alti-Salbutamol Inhalation Aerosol-Imogam Rabies-HT human
- Alti-Salbutamol Inhalation Aerosol-Imogen
- Alti-Salbutamol Inhalation Aerosol-Imotil
- Alti-Salbutamol Inhalation Aerosol-Imovax Rabies
- Alti-Salbutamol Inhalation Aerosol-Imovax Rabies human diploid cell
- Imodium Multi-Symptom Relief-Alti-sulfaSALAzine
- Imodium Multi-Symptom Relief-Alti-Valproic
- Imodium Multi-Symptom Relief-Altocor
- Imodium Multi-Symptom Relief-Altoprev
- Imodium Multi-Symptom Relief-Altreno
- Imodium Multi-Symptom Relief-Altreno Topical